Antimicrobial Therapy and COVID-19 — the 'Great Confrontation'

• Published in: Антибиотики и Химиотерапия Vol. 67; no. 9-10; pp. 63 - 68
• Main Authors: A. A. Zaytsev, A. М. Makarevich
• Format: Journal Article
• Language: Russian
• Published: LLC "Publishing House OKI" 29.12.2022
• Subjects: covid-19; inflammatory biomarkers; procalcitonin; аntimicrobial therapy
• ISSN: 0235-2990
• DOI: 10.37489/0235-2990-2022-67-9-10-63-68

The problem of antimicrobial therapy (AMT) for the new coronavirus infection has been the cornerstone of practical healthcare since its emergence to the present day. The article summarizes a number of problems concerning the unjustified prescription of AMT based on the data of foreign and domestic studies, as well as actual clinical practice. On the one hand, viral damage to the lung tissue during COVID-19 is difficult to distinguish from community-acquired or secondary bacterial pneumonia; it prompts clinicians to prevent possible bacterial complications in the lungs by prescribing broad-spectrum antibiotics starting from the first day. On the other hand, the presence of clear clinical and biological markers of bacterial pneumonia; and COVID-19 makes it possible not to use antibiotics in routine practice, at least in the early stages of treatment. The introduction of procalcitonin as a biomarker of bacterial infection in COVID-19 into everyday clinical practice has a reasonable, methodical, and scientific approach to prescribing antibiotics.